Put companies on watchlist
Vita 34 AG
ISIN: DE000A0BL849
WKN: A0BL84
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Vita 34 AG · ISIN: DE000A0BL849 · EQS - adhoc news (46 News)
Country: Germany · Primary market: Germany · EQS NID: 1218316
13 July 2021 12:39PM

Vita 34 AG: Shareholders of Vita 34 AG approve capital increase in connection with the proposed business combination with Polski Bank Komórek Macierzystych S.A. via share exchange


DGAP-Ad-hoc: Vita 34 AG / Key word(s): Mergers & Acquisitions/Capital Increase
Vita 34 AG: Shareholders of Vita 34 AG approve capital increase in connection with the proposed business combination with Polski Bank Komórek Macierzystych S.A. via share exchange

13-Jul-2021 / 12:39 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF APPLICABLE LAWS OR REGULATIONS

Vita 34 AG: Shareholders of Vita 34 AG approve capital increase in connection with the proposed business combination with Polski Bank Komórek Macierzystych S.A. via share exchange

Leipzig, 13. Juli 2021 - The shareholders of Vita 34 AG ("Vita 34") today approved the required capital increase in connection with the proposed business combination with Polski Bank Komórek Macierzystych S.A. ("PBKM") at the virtual extraordinary general meeting. The capital increase was resolved with a majority of 87.63% of the valid votes cast. A three-quarter majority of the share capital present at the resolution was required for the approval of the capital increase. The capital increase against contributions in kind with the exclusion of shareholders' subscription rights has a volume of up to EUR 12,280,560.00 and enables the creation of up to 12,280,560 new Vita 34 shares. These will be offered to certain PBKM shareholders under individual contribution agreements as well as to the free float PBKM shareholders in a voluntary public exchange offer ("Exchange Offer") in exchange for their shares in PBKM.

On 31 May 2021, Vita 34 signed a business combination agreement ("BCA") with PBKM, governing the terms and conditions of a business combination of the two companies. It was agreed in the BCA that Vita 34 will offer the shareholders of PBKM to exchange all their shares in PBKM for shares in Vita 34 by way of a contribution in kind (the "Proposed Transaction"). Vita 34 intends to offer the shareholders of PBKM 1.3 new Vita 34 shares for each one (1) PBKM share. The capital increase approved today provides the basis for the Proposed Transaction. The determination of the further details of the Exchange Offer will be made in a securities prospectus which is expected to be published until the end of September 2021.

Important Information

This announcement neither constitutes an offer to exchange or purchase nor the solicitation of an offer to exchange or purchase any securities. Moreover, this announcement neither constitutes an offer to buy nor the solicitation of an offer to buy any securities in PBKM or Vita 34. The final terms and further provisions regarding the Exchange Offer will be included in a securities prospectus once it has been approved by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht). Investors and holders of PBKM shares are strongly recommended to read the securities prospectus and all other documents in connection with the Exchange Offer as soon as they are published, as they will contain important information. Vita 34 may not initiate the Exchange Offer at all.

Subject to the exceptions described in the securities prospectus and any exceptions granted by the relevant regulatory authorities, an Exchange Offer is not being made, directly or indirectly, in or into those jurisdictions where to do so would constitute a violation pursuant to the laws of such jurisdiction.

In particular, the Vita 34 shares that are intended to be transferred to PBKM shareholders as consideration (the "Vita 34 Offer Shares") have not been, and will not be, registered under the United States Securities Act of 1933 as amended,(the "Securities Act"), or under the securities laws of any state, district or other jurisdiction of the U.S.A. The Vita 34 Offer Shares may not be offered, sold or delivered, directly or indirectly, to PBKM shareholders located with a domicile, registered office or habitual abode in the U.S.A. (the "U.S. Shareholders"), or to any agents, appointees, trustees, custodian banks or other persons acting for the account of benefit of any U.S. Shareholders, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.




Contact:
Dr. Wolfgang Knirsch (CEO), Falk Neukirch (CFO)

13-Jul-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: ir@vita34.de
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1218316

 
End of Announcement DGAP News Service

1218316  13-Jul-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1218316&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Vita 34 AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.